Search Results - "Munster, P.N."

Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours by Piha-Paul, S.A, Munster, P.N, Hollebecque, A, Argilés, G, Dajani, O, Cheng, J.D, Wang, R, Swift, A, Tosolini, A, Gupta, S

“…Abstract Background The phosphatidylinositol 3-kinase/protein kinase-B/mammalian target of rapamycin (PI3K-AKT-mTOR) signalling pathway is aberrantly activated…”
Get full text

551 Phase 1B study of CC-486 (oral azacitidine) in tumors associated with a viral etiology by von Hoff, D.D, Isambert, N, Lopez-Martin, J, Munster, P.N, Rasco, D.W, Bendell, J.C, Schellens, J.H.M, Tomaro, J, Sarmiento, R, Liu, K, Nguyen, A, Bray, G.L, Hatty, S.R, Di Martino, J.F, Le Tourneau, C

Get full text

411 A phase I trial of the histone deacetylase inhibitor panobinostat (LBH589) and epirubicin in patients with solid tumor malignancies by Moore, A.P, Thomas, S, Ryan, C.J, Jahan, T.M, DuBois, S.G, Chan, J.K, Thurn, K.T, Reinhert, A, Daud, A, Munster, P.N

Get full text

9234 Clinical experience with vorinostat: collated safety and tolerability data from patients with solid or hematologic malignancies by Siegel, D, Munster, P.N, Iwamoto, M, van Belle, S, Hussein, M, Belani, C, Robert, F, Galanis, E, Rizvi, S, Rubin, E.H

Get full text

Maintenance lenalidomide in primary CNS lymphoma by Rubenstein, J.L., Geng, H., Vu, K., Mannis, G., Formaker, P., Hwang, J., Munster, P.N., Damato, B.

Get full text

Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy by Campone, M., Bondarenko, I., Brincat, S., Hotko, Y., Munster, P.N., Chmielowska, E., Fumoleau, P., Ward, R., Bardy-Bouxin, N., Leip, E., Turnbull, K., Zacharchuk, C., Epstein, R.J.

“…This phase II study evaluated single-agent bosutinib in pretreated patients with locally advanced or metastatic breast cancer. Patients received oral bosutinib…”
Get full text

Randomized trial of lisinopril or carvedilol for the prevention of cardiotoxicity in patients with early stage HER2-positive breast cancer receiving trastuzumab by Munster, P.N., Krischer, J., Tamura, R., Bello-Matricaria, L., Fink, A., McCaskill-Stevens, W., Guglin, M.

Get full text

A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma by Thomas, S., Aggarwal, R., Jahan, T., Ryan, C., Troung, T., Cripps, A.M., Raha, P., Thurn, K.T., Chen, S., Grabowsky, J.A., Park, J., Hwang, J., Daud, A., Munster, P.N.

“…Treatment options for sarcoma are limited. Histone deacetylase inhibitors increase the efficacy of topoisomerase II inhibitors by promoting access to chromatin…”
Get full text

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors by Hong, David S, Fakih, Marwan G, Strickler, John H, Desai, Jayesh, Durm, Gregory A, Shapiro, Geoffrey I, Falchook, Gerald S, Price, Timothy J, Sacher, Adrian, Denlinger, Crystal S, Bang, Yung-Jue, Dy, Grace K, Krauss, John C, Kuboki, Yasutoshi, Kuo, James C, Coveler, Andrew L, Park, Keunchil, Kim, Tae Won, Barlesi, Fabrice, Munster, Pamela N, Ramalingam, Suresh S, Burns, Timothy F, Meric-Bernstam, Funda, Henary, Haby, Ngang, Jude, Ngarmchamnanrith, Gataree, Kim, June, Houk, Brett E, Canon, Jude, Lipford, J. Russell, Friberg, Gregory, Lito, Piro, Govindan, Ramaswamy, Li, Bob T

“…Activating mutations in RAS , the most commonly mutated oncogene in human cancer, result in stimulating growth of cells. Sotorasib inhibits the G12C mutant…”
Get full text

Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates by Kelley, R.K., Nimeiri, H.S., Munster, P.N., Vergo, M.T., Huang, Y., Li, C.-M., Hwang, J., Mulcahy, M.F., Yeh, B.M., Kuhn, P., Luttgen, M.S., Grabowsky, J.A., Stucky-Marshall, L., Korn, W.M., Ko, A.H., Bergsland, E.K., Benson, A.B., Venook, A.P.

“…Based upon preclinical evidence for improved antitumor activity in combination, this phase I study investigated the maximum-tolerated dose (MTD), safety,…”
Get full text

Responses and durability of clinical benefit in non-small cell lung cancer treated with pegilodecakin in combination with anti-PD-1 inhibitors by Garon, E.B., Wong, D.J., Schneider, J.G., Aljumaily, R., Korn, W.M., Patel, M.R., Autio, K.A., Papadopoulos, K.P., Naing, A., Gabrail, N., Munster, P.N., Goldman, J., Hung, A., Oft, M., Leveque, J., Spigel, D.R.

Get full text

556 Histone deacetylase inhibitors induce chromatin decondensation by down-regulation of proteins involved in the maintenance of heterochromatin by Marchion, D.C., Bicaku, E., Daud, A.I., Sullivan, D.M., Munster, P.N.

Get full text

293 POSTER Phase I trial of the histone deacetylase inhibitor valproic acid with the topoisomerase I inhibitor, karenitecin in advanced melanoma by Daud, A., Gump, J.L., Neuger, A., DeConti, R.H., Bastine, S., Mintz, M., Hausheer, F.H., Lush, R., Sullivan, D.M., Munster, P.N.

Get full text

307 POSTER Phase I study of arsenic trioxide in subjects with hepatocellular cancer and varying levels of hepatic dysfunction by Johns, M., Chodkiewicz, C., Dinwoodie, W.R., Munster, P.N., Daud, A.I., Simon, G.R., Monet, B., Brown, P., Loh, E., Garrett, C.R.

Get full text

334 First-in-human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of oral cp-724, 714, a selective, small molecule inhibitor of her2 in patients with advanced cancer by Munster, P.N., Tolcher, A.W., Britten, C.D., Gelmon, K., Moulder, S., Minton, S., Mita, M., Noe, D., Pierce, K.J., Letrent, S.P.

Get full text